Announcement under Regulation 30 (LODR)-Investor Presentation

Please find enclosed herewith the investor presentation, which we shall be uploading on our website after sending this letter to you.

16 days ago

INVESTOR PRESENTATION

Tweet

Sentiments detected

Positive 29
  • Expanding presence in Rest of World markets

  • For plaque psoriasis - Launched in US in October 2018 & in Australia in Dec-2018, Phased launch in Europe by Almirall starting December 2018 onwards - Long term clinical data shows that the significant response rate seen in 52 & 64 weeks were Ilumya/ maintained over five years Ilumetri • Evaluating new indications for Ilumya - Phase-2 data shows potential to improve joint & skin symptoms of Psoriatic Arthritis.

  • Indication - For reduction of elevated IOP in patients with open-angle glaucoma or ocular Xelpros hypertension - BAK (Benzalkonium chloride)

  • Strengthens Taro’s OTC portfolio 2021 In-licensed Winlevi ® (clascoterone cream 1%) US & Canada Topical treatment of acne vulgaris 2020 Exclusive licensing agreement with Himka for Ilumya Middle East & North Africa Registration and commercialization of the product in all Middle East & North Africa (MENA) markets.

  • 2020 Licensing agreement with SPARC for SCD-044 Global Potential treatment for psoriasis, atopic dermatitis & other auto-immune disorders 2020 In-licensed Triferic brand from Rockwell Medical Inc. (USA) India Expands nephrology portfolio in India - for treating anaemia in hemodialysis patients.

  • 2019 Licensing agreement with Astrazeneca UK for ready-to-use infusion oncology products Mainland China Access to oncology market in Mainland China 2019 Licensing agreement with CMS for Tildrakizumab, Cequa & 8 generic products

  • Deals Country Rationale 2016 Acquired Biosintez Russia Local manufacturing capability to enhance presence in Russian market 2016 Licensing agreement with Almirall for Tildrakizumab for Psoriasis Europe Access to European market for Tidrakizumab 2016

  • Acquired 14 brands from Novartis Japan Entry into Japan 2016 Distribution agreement with AstraZeneca India Distribution services agreement in India for brand “Oxra” & “Oxramet”® (brands of dapagliflozin, used for diabetes treatment) 2015 Acquired InSite Vision Inc. US Strengthens branded ophthalmic portfolio in U.S. 2015 Distribution agreement with AstraZeneca India Distribution services agreement in India for brand “Axcer”® (brand of ticagrelor, used for the treatment of acute coronary syndrome)

  • Global Markets Strengthen position in the Global Generic Pharma Industry, No.1 Pharma Company in India & Strong positioning in Emerging Markets 2014 In-licensing agreement with Merck for Tildrakizumab a biologic for psoriasis Global Markets

  • FY18 - US FDA approval for Ilumya - Tildrakizumab filing in US & Europe FY17 • Acquired Ocular Technologies giving access to Cequa, a product for dry eyes.

  • No. 1 ranked by prescriptions with 11 different classes of doctors Chronic Segment - Market leader in the chronic segment Acute Segment - Strong positioning in the acute segment Product Offering •

  • Specializes in technically complex products and offers a complete therapy basket Strong Brand Positioning** - 33 brands in the country’s top 300 pharmaceutical brands •

  • 18% of India revenues – low De-risked Growth** product concentration • Growth driven by a basket of brands Sales Strength - 11,149 strong field force ** - As per AIOCD AWACS data for 12 months ended June’22 ## - As per SMSRC data for Feb’22

  • Leadership in key therapeutic areas* Number 1 Ranking with 11 Doctor Categories*

  • Well trained and scientifically oriented sales representatives Impact of sales force 11.4 team with strong performance expansion track record 10.0 9.4 8.6 8.8 - Field force with highest productivity amongst key players in India - Expanded sales force strength in FY21 to enhance geographical & doctor reach and improve brand focus

  • Favourable macroeconomic parameters to drive pharmaceutical consumption in the long-term Local Manufacturing •

  • Expanding basket of products including specialty brands, injectable & hospital products as well as products for retail market Focus • Development and commercialization of complex generics and differentiated products to drive sustainable and profitable growth Sales Force •

  • At Canada, Japan, Australia, Israel and Hungary + supplies from India facilities •

  • Amongst the top 10 consumer healthcare companies Global Presence - Presence in about 20+ countries Focus Markets - Romania, Russia, South Africa, Nigeria, Myanmar, Ukraine, Poland, Thailand, Belarus, Kazakhstan, Nepal, Morocco, UAE and Oman Strong Brand Equity • Enjoys strong brand equity in 4 countries Sales Force • Promoted through dedicated sales force in each market Strong Positioning •

  • Backward integration provides cost competitiveness and supply reliability Customers •

  • R&D spend at 5.8% of sales for FY22 • Strong cash flows & large scale to support R&D investments Capabilities • Capabilities in finished dosage development, biological support, chemistry and new drug development • Approx.

  • Strong team of intellectual property experts supporting R&D

  • Global Manufacturing Presence World Class Manufacturing Infrastructure Extensive Global Footprint • 43 manufacturing facilities across India, the Americas, Asia, Africa, Australia and Europe Integrated Network • Vertically integrated network across six continents enabling high quality, low cost and a quick market entry across the geographies •

  • FY20 FY21 FY22 Growth (%)

  • Enhance share of specialty/branded business US Business •

  • Maintain leadership position in a fiercely competitive market Business • Continuously innovate to ensure high brand equity with doctors •

  • Gain critical mass in key markets EM & RoW •

  • Enhance product basket in emerging markets

  • Expanding presence in Rest of World markets

Negative 4
  • 43.9 bn provision (for US litigation related to Ranbaxy Meijer & Others Rs. 39,357 mn, Japan (plant) loss Rs. 382 mn, Dexasite impairment Rs. 1,503 mn., US MDL (Taro) Rs.

  • Sales Break-up

  • 43.9 bn provision (for US litigation related to Ranbaxy Meijer & Others Rs. 39,357 mn, Japan (plant) loss Rs. 382 mn, Dexasite impairment Rs. 1,503 mn., US MDL (Taro) Rs.

  • 43.9 bn provision (for US litigation related to Ranbaxy Meijer & Others Rs. 39,357 mn, Japan (plant) loss Rs. 382 mn, Dexasite impairment Rs. 1,503 mn., US MDL (Taro) Rs.

Mentioned Phrases & Organizations

Important keywords detected (20+)

sales (34)
pharma (30)
specialty (25)
india (24)
market (24)
adjusted (23)
related (21)
across (20)
products (19)
japan (19)
launched (19)
taro (18)
provision (18)
sun (17)
manufacturing (17)
net (17)
generics (16)
global (15)
branded (15)
data (15)

Organizations identified (10+)

Sun Pharma (5)
IQVIA (5)
USFDA (4)
Novartis (4)
Ilumya (3)
Cequa (3)
DOJ (3)
US MDL (3)
SUN HOUSE (2)
CTS (2)

Tables extracted (3)

YearDealsCountryRationale
2022Expanded Winlevi ® licensing agreement to include Japan, Australia, New Zealand, Brazil, Mexico & Russia marketsJapan, Australia, New Zealand, Brazil, Mexico and RussiaTopical treatment of acne vulgaris
2022Acquired Uractiv TM Portfolio from Fiterman PharmaRomaniaExpand non-prescription product basket in Romania and neighbouring markets
2022Taro (Sun's subsidiary company) acquired Alchemee Business from GaldermaUS, Japan, Canada"Acquired the ""Proactiv"", ""Restorative Elements"" and ""In Defense of Skin"" brands. Strengthens Taro’s OTC portfolio"
2021In-licensed Winlevi ® (clascoterone cream 1%)US & CanadaTopical treatment of acne vulgaris
2020Exclusive licensing agreement with Himka for IlumyaMiddle East & North AfricaRegistration and commercialization of the product in all Middle East & North Africa (MENA) markets.
2020Licensing agreement with SPARC for SCD-044GlobalPotential treatment for psoriasis, atopic dermatitis & other auto-immune disorders
2020In-licensed Triferic brand from Rockwell Medical Inc. (USA)IndiaExpands nephrology portfolio in India - for treating anaemia in hemodialysis patients.
2019Licensing agreement with Astrazeneca UK for ready-to-use infusion oncology productsMainland ChinaAccess to oncology market in Mainland China
2019Licensing agreement with CMS for Tildrakizumab, Cequa & 8 generic productsGreater ChinaAccess to Greater China market
2018Acquired Pola Pharma in JapanJapanAccess to Japanese dermatology market.
2016Acquired global rights for Cequa & OdomzoGlobalEnhances specialty pipeline.
YearDealsCountryRationale
2016Acquired BiosintezRussiaLocal manufacturing capability to enhance presence in Russian market
2016Licensing agreement with Almirall for Tildrakizumab for PsoriasisEuropeAccess to European market for Tidrakizumab
2016Acquired 14 brands from NovartisJapanEntry into Japan
2016Distribution agreement with AstraZenecaIndiaDistribution services agreement in India for brand “Oxra” & “Oxramet”® (brands of dapagliflozin, used for diabetes treatment)
2015Acquired InSite Vision Inc.USStrengthens branded ophthalmic portfolio in U.S.
2015Distribution agreement with AstraZenecaIndiaDistribution services agreement in India for brand “Axcer”® (brand of ticagrelor, used for the treatment of acute coronary syndrome)
2015Sun Pharma – Ranbaxy MergerGlobal MarketsStrengthen position in the Global Generic Pharma Industry, No.1 Pharma Company in India & Strong positioning in Emerging Markets
2014In-licensing agreement with Merck for Tildrakizumab a biologic for psoriasisGlobal MarketsStrengthening the specialty product pipeline
2014Acquired PharmalucenceUSAccess to sterile injectable capacity in the US
2012Acquired DUSA Pharma, Inc.USAccess to specialty drug-device combination in dermatology segment
2010Acquired Taro Pharmaceutical Industries Ltd.IsraelAccess to dermatology generic portfolio Manufacturing facilities at Israel & Canada
1997Acquired CaracoDetroit, USEntry into US Market
US Business Sales in Rs. billion137138
135138
114
107
105
101
87

Features are experimental.